Randall King

Randall W. King MD, PhD is a Cofounder of Proteostasis Therapeutics and Associate Professor in the Department of Cell Biology at Harvard Medical School, where his laboratory develops novel chemical tools to study ubiquitin-dependent protein breakdown and uses high-throughput siRNA screening to identify new genes required for cancer cell division.

Prior to joining the faculty at Harvard Medical School, Dr. King was a fellow at the Institute of Chemistry and Cell Biology at Harvard, where he developed new approaches in chemical genetics, including instrumentation used for the synthesis and screening of arrayed split-pool chemical libraries. Dr.King co-founded the drug discovery company Kalypsys in 2001, and served on its science advisory board for four years.

He received an MD from Harvard Medical School after receiving a PhD from Mark Kirschner's laboratory at the University of California, San Francisco (UCSF). He received a B.A. degree in chemistry from Carleton College in 1987.

Randall King is the Cofounder at Proteostasis Therapeutics, based in United States, North America. With a background in Biotechnology, Randall King has a rich history of leadership and innovation.Randall King studied BA Chemistry at Carleton College. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.